"These tariffs have dramatically increased the cost of producing our gear—by more than double in some cases. We’ve absorbed ...

Clinical data on track for Q4 2025 from Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLC; Expansion of investigator sponsored Phase 0/1 trial into newly di ...

Black Diamond Therapeutics, Inc.’s BDTX share price has dipped by 5.39%, which has investors questioning if this is right ...

Black Diamond Group Limited CALGARY, Alberta, May 08, 2025 (GLOBE NEWSWIRE) -- Black Diamond Group Limited (TSX: BDI, OTCQX:BDIMF) (“Black Diamond” or the “Company”) announces that it has ...

Black Diamond Therapeutics, Inc.’s BDTX share price has surged by 6.45%, which has investors questioning if this is right time to sell.

Fancy an adrenaline rush? Check out Black Diamond's latest climbing film to see Austrian daredevil Babsi Zangerl become the ...

Black Diamond Group Limited ("Black Diamond", the "Company" or "we"), (TSX:BDI, OTCQX:BDIMF), a leading provider of space rental and workforce accommodation solutions, ...

Black Diamond Group Limited reported a significant increase in profit for the first quarter of 2025, with earnings per share (EPS) of $0.09, slightly below the forecast of $0.0902. The company’s ...

During the prior NCIB of the Company, which will terminate on May 9, 2025, the Company obtained approval to purchase 4,542,945 Common Shares, and as of April 30, 2025, purchased 623,950 Common Shares ...